Please feel free to forward to fellow researchers and share news of our journal | Dear Colleague, We are delighted to announce the publication of Volume 4, Issue 1 of our Kidney Cancer journal. This issue includes an editorial on nephrectomy status in the context of cabozantinib treatment, two systematic review articles, and three research articles, plus a new Clinical Trials Corner contribution. View all the open access content via the links below. | Call for Papers As a member of our community, we would like to invite you to submit your own research articles to the journal, which offers contributing authors many benefits: • First class Editorial Board
• Rigorous peer review and speedy manuscript processing
• Rapid online publication (pre-press) on acceptance
• The first three volumes freely available to all readers
• Articles accepted this year will be published Open Access with no article processing fee Submit your manuscript online via msTracker
View detailed Instructions to Authors
Aims and Scope Kidney Cancer is an international, multidisciplinary journal that provides an invaluable and indispensable platform for the many collaborative, transdisciplinary, and translational efforts to help treat and finally cure this malignancy. Best wishes, Primo N. Lara Jr, MD
UC Davis Comprehensive Cancer Center
Sacramento, CA, USA
Email: kca@iospress.com Peter Mulders, MD, PhD
Radboud UMC
Nijmegen, The Netherlands
Email: kca@iospress.com Editors-in-Chief
Sign up now for Kidney Cancer news
Join the conversation at: twitter.com/KCA_Journal | All articles are freely available online for all to read, download and share. Editorial Nephrectomy Status in the Context of Cabozantinib Treatment
Esteghamat, Naseem | Lara, Primo N. | Parikh, Mamta Systematic Reviews The Prognostic Value of DNA Methylation Markers in Renal Cell Cancer: A Systematic Review
Peters, Inga | Merseburger, Axel S. | Tezval, Hossein | Lafos, Marcel | Tabrizi, Pouriya Faraj | Mazdak, Mehrdad | Wolters, Mathias | Kuczyk, Markus A. | Serth, Jürgen | von Klot, Christoph-A.J. A Systematic Review of Systemic Treatment Options for Advanced Non-Clear Cell Renal Cell Carcinoma
Osterman, Chelsea K. | Rose, Tracy L. Research Articles Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma
Tannir, Nizar M. | Powles, Thomas | Escudier, Bernard | Donskov, Frede | Grünwald, Viktor | Sternberg, Cora N. | Schmidinger, Manuela | Schöffski, Patrick | Szczylik, Cezary | et al. Thickness of Perirenal Fat Predicts the Growth Pattern of Renal Cell Carcinoma
Kashiwagi, Eiji | Imada, Kenjiro | Abe, Tatsuro | Kinoshita, Fumio | Monji, Keisuke | Shiota, Masaki | Takeuchi, Ario | Inokuchi, Junichi | Tatsugami, Katsunori | Eto, Masatoshi Prognostic Value of Histologic Subtype and Treatment Modality for T1a Kidney Cancers
Siev, Michael | Renson, Audrey | Tan, Hung-Jui | Rose, Tracy L. | Kang, Stella K. | Huang, William C. | Bjurlin, Marc A. Other Content Clinical Trials Corner: A Promising New Drug Class in Treating Metastatic Renal Cell Carcinoma
Parikh, Mamta | Most Read Kidney Cancer Articles in Q1 2020 Listing articles published only in 2018 & 2019 so you can read the most popular recent content Diagnostic Imaging for Solid Renal Tumors: A Pictorial Review (Review Article in Vol.2, Iss.2, 2018)
van Oostenbrugge, Tim J. | Fütterer, Jurgen J. | Mulders, Peter F.A. Real-World Results from One Year of Therapy with Tivozanib (Research Article in Vol.3, Iss.4, 2019)
Staehler, Michael | Spek, Annabel K. | Rodler, Severin | Schott, Melanie | Casuscelli, Jozefina | Mittelmeier, Lena | Schlemmer, Marcus What Comes After Immuno-Oncology Therapy for Kidney Cancer? (Review Article in Vol.3, Iss.2, 2019)
Zahoor, Haris | Duddalwar, Vinay | D’Souza, Anishka | Merseburger, Axel S. | Quinn, David I. Immune Checkpoint Inhibition, the Key to Success in Renal Cell Carcinoma? (Review Article in Vol.3, Iss.4, 2019)
Reijm, E.A. | van Thienen, J.V. | Wilgenhof, S. | Bex, A. | Haanen, J.B.A.G. A Review of Papillary Renal Cell Carcinoma and MET Inhibitors (Review Article in Vol.3, Iss.3, 2019)
Rhoades Smith, Katherine Emilie | Bilen, Mehmet Asim | | KCA's New Social Media Editor: Neeraj Agarwal, MD | We are pleased to welcome Neeraj Agarwal, MD as our new social media edtior! Dr. Agarwal is a physician and an investigator at the Huntsman Cancer Institute at the University of Utah, USA, and he is also an Associate Editor of Kidney Cancer. Dr. Agarwal will be sharing journal content and engaging with the kidney cancer research community via Twitter. He comments: "Twitter has become a powerful and a widely used tool for rapid dissemination of critical scientific data in a timely fashion. I am very happy to be a part of that." If you are not yet interacting with us on social media yet, why not take the time today to follow on Twitter? You can get our attention by tagging the KCA account @KCA_Journal or using the hashtag #KCAjournal. | | Kidney Cancer Association News | Open For Entries: Young Investigator & Advanced Discovery Awards The Kidney Cancer Association Young Investigator Awards (YIAs) and Advanced Discovery Awards (ADAs) are now open for entries. A total of $1.3 million in funding will be available: four $75,000 YIAs and two $500,000 ADAs. YIAs encourage promising researchers in urology and clinical oncology who are planning to pursue an investigative career in kidney cancer. ADAs – a new award established in 2019 – promote collaboration between established clinicians and translational researchers to propose new, impactful research. All grant proposals will be evaluated by an independent panel of reviewers, who are recognized experts in the field. They will conduct a blinded, scored review of all applications received. Further details about the grant application process can be obtained here. | Please Share Kidney Cancer News With Your Colleagues Help Spread the News! | If you know of any colleagues or fellow researchers who are not yet signed up to receive the newsletter, we invite you to share this mailing with them. Click on the visual or access the sign-up link here. Kidney Cancer has an active social media presence. If you are not yet interacting with the journal on social media, why not take the time today to follow us on Twitter? Be part of the discussion! | You are receiving this mailing as you are signed up to receive news from KCA.
You can unsubscibe or alter your preferences at any time by clicking the links below. | |
